We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mersana Therapeutics Inc | NASDAQ:MRSN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.035 | 1.00% | 3.535 | 3.53 | 3.54 | 3.57 | 3.49 | 3.55 | 53,859 | 15:11:39 |
Details of the poster display and discussion are as follows:
Poster Title: Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.Abstract Number: 3010Date: June 1, 2019Poster Display: 8:00 AM – 11:00 AM C.T., Location – Hall A, Poster Board #2Poster Discussion: 3:00 PM – 3:22 PM C.T., Location – E450Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms and its modular Synthemer scaffold to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC adenocarcinoma, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Contact:
Investor ContactSarah Carmody, 617-844-8577scarmody@mersana.com
Media ContactPaul Kidwell, 617-680-1088pkidwell@mersana.com
1 Year Mersana Therapeutics Chart |
1 Month Mersana Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions